14th Alzheimer’s & Parkinson’s Drug Development Summit

The site is part of the Hanson Wade division at Hanson Wade Group. About Us | Products | Contact Us

Hanson Wade Conferences Limited is registered in England & Wales, number 16983906. Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.

This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

The approval of the first anti-amyloid drugs has resurrected the neurodegenerative disease space, opening the door for enhanced competition and innovation to develop novel disease-modifying therapies. However, as challenges remain in the clinical adoption of Lecanemab and Donanemab, the field needs to navigate the move towards disease-modifying therapeutics.

Capitalizing on the surge of innovation across new targets, lessons learned from clinical setbacks, groundbreaking progress in blood-based diagnostics, and more, the 14th Alzheimer’s & Parkinson’s Drug Development Summit returned as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical and regulatory.

At ProMIS Neurosciences, we appreciate the size of the APDD meeting and the variety of participants. There is ample opportunity to make connections and discuss important issues among large and small groups, and large and small organizations.